| Drug General Information |
| Drug ID |
D0G0YZ
|
| Former ID |
DIB018048
|
| Drug Name |
UK-356202
|
| Synonyms |
compound 13j [PMID: 15149680]; UK-356,202
|
| Drug Type |
Small molecular drug
|
| Indication |
Myocardial hypertrophy [ICD10:I51.7]
|
Clinical trial |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C17H13ClN4O2
|
| InChI |
InChI=1S/C17H13ClN4O2/c18-14-8-21-15(22-17(19)20)13-7-10(4-5-12(13)14)9-2-1-3-11(6-9)16(23)24/h1-8H,(H,23,24)(H4,19,20,21,22)
|
| InChIKey |
UXNWIRHZMHGOCE-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14900318, 15297608, 24171947, 45632108, 46516387, 75570363, 103332475, 104035914, 125755599, 129434949, 142418272, 152105818, 163151609, 178103157, 232160470
|
| Target and Pathway |
| Target(s) |
Urokinase-type plasminogen activator |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Complement and coagulation cascades
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
PANTHER Pathway
|
Blood coagulation
|
|
Plasminogen activating cascade
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Beta1 integrin cell surface interactions
|
|
E2F transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
amb2 Integrin signaling
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
Beta2 integrin cell surface interactions
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
|
FGF signaling pathway
|
|
Reactome
|
Dissolution of Fibrin Clot
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
Complement and Coagulation Cascades
|
|
Endochondral Ossification
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
Blood Clotting Cascade
|
|
Dissolution of Fibrin Clot
|
|
Osteopontin Signaling
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. |
|---|
